Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy

NCT01583543 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01583543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01583543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
November 30, 2014
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ewing's sarcoma